Stock COSMO PHARMACEUTICALS SA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News COSMO Pharmaceuticals SA Swiss Exchange

Equities

LU1202320294

End-of-day quote Swiss Exchange
Other stock markets
- CHF - Intraday chart for COSMO Pharmaceuticals SA
Apr. 26 Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 CI
Apr. 25 Cosmo Pharmaceuticals Names New CEO, Chairman MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
NE
Cosmo Pharmaceuticals N : has received approval of an extension in respect of the publication and the filing of its annual report 2023
PU
Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024
CI
Cosmo Pharmaceuticals Names New CEO, Chairman
MT
Cosmo Announces Leadership Changes
NE
Cosmo and Medtronic unveil the future of AI in GI, Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
AQ
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
NE
Cosmo and Medtronic unveil the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
PU
Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day
Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024
CI
Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2024 and Revenue Guidance for 2025
CI
Transcript : Cosmo Pharmaceuticals N.V., 2023 Earnings Call, Mar 20, 2024
Cosmo Pharmaceuticals N : ESG Report 2023
PU
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
NE
Cosmo Pharmaceuticals' FY23 Profit, Revenue Drops
MT
Cosmo Pharmaceuticals N : reports excellent preliminary unaudited Full Year 2023 core financial results – Record guidance for 2024 – Doubles dividend to € 2.00 per share
PU
Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cosmo Pharmaceuticals Partner Gets Regulatory Approval for Acne Treatment in Australia
MT
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
NE
Cosmo Pharmaceuticals N : announces approval of Winlevi® in Australia
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COPN Stock
  4. Stock
  5. News COSMO Pharmaceuticals SA